Skip to main content

$11.22 -0.22 (-1.92%)

High

$11.49

Low

$11.20

Trades

4,718

Turnover

$7,499,551

Volume

664,557
30 June 2023 at 4:12pm
Register to track TLX and receive email alerts.

ASX Announcements (7d)

-

Twitter Mentions (7d)

0+

AFR Articles (7d)

-

News Articles (7d)

1+
Subject
TLX Ann: Chairmans Address to AGM

TLX Ann: Phase III Prostate Cancer Therapy Clinical Trial Commences

TLX Ann: Executive Leadership Appointments and Establishment of APAC

TLX Ann: Telix Appoints Mr Richard Valeix as EMEA President

TLX Ann: Manufacturing Agreement with Global Medical Solutions

TLX Ann: Activities Report and App 4C for quarter ended 31 March 2021

TLX Ann: Japanese Renal Cancer Imaging Trial Meets Study Objectives

TLX Ann: Launch of International NOBLE Registry for SPECT Imaging

TLX Ann: TGA commences priority evaluation process for Illuccix

TLX Ann: AGM Notice of Meeting and Explanatory Memorandum

TLX Ann: Agreement with GRAM for commercial manufacture of Illucix

TLX Ann: Cleansing Notice - shares issued upon exercise of options

TLX Ann: App 2A - quotation of shares issued upon exercise of options

TLX Ann: Global Agreements with ITM for Lutetium-177 Supply

TLX Ann: S&P DJI Announces March 2021 Quarterly Rebalance

TLX Ann: Cleansing Notice - issue of shares upon exercise of options

TLX Ann: App 2A - quotation of shares on exercise of options

TLX Ann: Cleansing Notice - issue of shares upon exercise of options

TLX Ann: App 2A - quotation of shares on exercise of options

TLX Ann: 2020 Annual Report

TLX Ann: Appendix 4E - Results for announcement to the market

TLX Ann: Corporate Governance Statement year ended 31 December 2020

TLX Ann: Appendix 4G - key to governance disclosures

TLX Ann: Shareholder update - year ended 31 December 2020

TLX Ann: PMDA clearance to commence Prostate Cancer Imaging Study

TLX Ann: Czech Republic Grants National Authorisation for TLX591 Kit

TLX Ann: Notification of Conference Call for FY2020 Results

TLX Ann: Collaboration with Heidelberg University Hospital

TLX Ann: Telix Pursues Direct Benelux Product Distribution

TLX Ann: Appendix 3G - issue of unlisted share options

TLX Ann: Appendix 4C and Activities Report for December 2020 Quarter

TLX Ann: First US patients dosed in Ph III ZIRCON trial

TLX Ann: TLX101 Glioblastoma Therapy - Clinical Update

TLX Article: ASX up 1.2pc; Rio Tinto’s new CEO; Afterpay hits record

TLX Ann: Cleansing Notice under section 708A Corporations Act

TLX Ann: Appendix 2A - issue of shares from exercise of options

TLX Ann: Change in substantial holding

TLX Ann: New Drug Submission filed with Health Canada for TLX591-CDx

TLX Ann: Urologic Oncology Alliance with Mauna Kea Technologies

TLX Ann: IP Agreement with U Southampton for access to TRALA data

TLX Ann: Cleansing Notice under section 708A Corporations Act

TLX Ann: Appendix 2A - issue of shares from exercise of options

TLX Ann: Appendix 2A - shares issued as consideration for acquisition

TLX Ann: Telix Completes Acquisition of TheraPharm GmbH

TLX Ann: Telix and Kanazawa University Phase I trial of TLX591-CDx

TLX Ann: Release of shares from voluntary escrow

TLX Ann: FDA New Drug Application for TLX591-CDx Proceeds to Review

TLX Ann: TGA Priority Review Granted for Prostate Cancer Imaging

TLX Ann: Overview of ProstACT Phase III Study - Investor supplement

TLX Ann: ProstACT Phase III Study Clinical Development Update

Register to track TLX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC